Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (950)	11/18/1997 6:28:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 2173

D. Right, The revised trial should help determine why the results were not stronger. However, since insulin had such a major effect, its clear that the Pramlintide effect is considerably weaker than the insulin effect, and the failure to demonstrate an effect in about 1/2 of the type II patients, again shows that the mechanism is not as simple as your model suggests. I also suspect that if Pramlintide were given at a higher dose, it would also create liver problems in a subpopulation. I believe that the Rezulin liver problem is more related to the liver clearing the drug, than targeting liver cells to alter gene expression.